Sofinnova Partners
Finance · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
FrancePhone Number
+32 92610684Website
www.sofinnova.frRevenue
<$5 MillionIndustry
About Sofinnova Partners
Sofinnova Partners Org Chart
Is Sofinnova Partners your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Sofinnova Partners recently announced quarterly report
Check out if Sofinnova Partners is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Sofinnova Partners
Sofinnova Partners, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Sofinnova Partners launches new products
Check if Sofinnova Partners has recently received funding, and reach out quickly before it becomes old news!
Click to see if Sofinnova Partners had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Sofinnova Partners has new funding data
Recommended Actions
Reach out to Masked Content who joined Sofinnova Partners as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Sofinnova Partners is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Sofinnova Partners is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Sofinnova Partners.
Sofinnova Partners Tech Stack
A closer look at the technologies used by Sofinnova Partners
Most Recent Scoops
Sofinnova Partners News & Media
Sofinnova closes €650m healthcare fund for early-stage ventures
The fund will participate in follow-on and initial rounds, focusing on biotech and medtech ventures across core markets.Sofinnova Partners secures €650M to back breakthroughs in biopharma and medical technology
Life sciences venture capital firm Sofinnova Partners today announced the close of its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million), greatly exceeding its initial target....Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech
Sofinnova Partners has closed its new investment fund, Capital XI, at €650m, far exceeding its original target. The early-stage biotech and medtech-focused fund will invest mostly in Series A, but also seed financings of companies, including oncology, inflammation and immunology, CNS, and cardio-metabolic diseases. Sofinnova Capital XI closes at €650m to expand early-stage biotech investing, backing seed and Series A companies in Europe and the US in innovative therapies.SafeHeal Closes €35M Series C Equity Financing
SafeHeal, a Paris, France- and Tampa, FL-based colorectal cancer surgery company, raised €35M in Series C equity funding. The round was led by Solar Eclipse with new investors Gideon Strategic Partners and M&L Healthcare, part of M&L Group, and returning investors Sofinnova Partners. The company intends to use the funds to complete its IDE Pivotal […] The post SafeHeal Closes €35M Series C Equity Financing appeared first on FinSMEs.
Top Finance Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the U.S. and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value... Read More